Melanoma

Advanced Health Intelligence to provide Biometric Health Screening in new Collaboration between Bearn and OnCore Innovations Inc.

HighlightsAHI partner Bearn LLC signs new collaboration with OnCore Innovations Inc.AHI biometrics to be used in Bearn and OnCore platform.OnCore…

1 year ago

IMUNON Appoints Dr. Patrick Ott to its Scientific Advisory Board

Renowned Daner-Farber Cancer Institute researcher will advise on the development of IMUNON’s FixPlas™ and Indiplas™ modalities in immuno-oncology. LAWRENCEVILLE, N.J.,…

1 year ago

Immunocore announces upcoming presentation and posters at ESMO 2023

Immunocore announces upcoming presentation and posters at ESMO 2023 Long-term survival data for KIMMTRAK in previously untreated patients with metastatic…

1 year ago

Coherus Announces Resubmission of Biologics License Application (BLA) Supplement for UDENYCA® ONBODY™

– Resubmission follows the satisfactory resolution of the FDA’s review of inspection findings at the third-party filler – REDWOOD CITY, Calif.,…

1 year ago

Coherus Applauds Congressional Designation of September 30th as Rare Cancer Day

- Bipartisan resolution highlights the challenges patients with rare cancers face and raises awareness and supports efforts to improve early…

1 year ago

Vaccinex Announces Pricing of $9.6 Million Public Offering

ROCHESTER, N.Y., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX) (“Vaccinex” or the “Company”), a clinical-stage biotechnology company…

1 year ago

Molecular Templates Announces the Appointment of Dr. Maurizio Voi to the Role of Chief Medical Officer

AUSTIN, Texas, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical…

1 year ago

Sensus Healthcare Sells Superficial Radiotherapy System to Cape Cod Hospital

Continues SRT-100+™ customer expansion to hospital oncology departments for the outpatient treatment of non-melanoma skin cancersBOCA RATON, Fla. , Sept.…

1 year ago

IMUNON Reports Interim Progression-Free Survival and Overall Survival Data in Phase 1/2 OVATION 2 Study in Advanced Ovarian Cancer

Intent-to-treat population shows 9-month OS improvement over control arm Subgroup of patients treated with IMNN-001 + PARPi shows meaningful PFS…

1 year ago

Onconova Therapeutics to Present a Late-Breaking Abstract on Rigosertib at the 2023 EADV Congress

NEWTOWN, Pa., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”, the “Company”), a clinical-stage biopharmaceutical company…

1 year ago